INT275725

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 3.41
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
neurons 1
xn (Mus musculus)
Pain Link Frequency Relevance Heat
Potency 14 5.00 Very Low Very Low Very Low
vagus nerve 7 5.00 Very Low Very Low Very Low
Somatostatin 7 5.00 Very Low Very Low Very Low
anesthesia 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 105 99.96 Very High Very High Very High
Death 28 98.44 Very High Very High Very High
Diabetes Mellitus 126 97.56 Very High Very High Very High
Disease 175 97.20 Very High Very High Very High
Insulin Resistance 35 87.92 High High
Targeted Disruption 7 83.20 Quite High
Parkinson's Disease 7 81.64 Quite High
Aging 14 78.16 Quite High
Neurodegenerative Disease 7 71.96 Quite High
Pheochromocytoma 7 64.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We show that, similar to effects on apoptosis, dimerization of HN is essential for its actions on glucose metabolism.
HN Binding (dimerization) of associated with apoptosis
1) Confidence 0.06 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 0.22 Pain Relevance 0
Specifically, there were no differences in GIR (Fig. 2D), HGP (Fig. 2E, F) or peripheral glucose uptake (Fig. 2G, H) between the groups that received the DD HN and controls.


HN Binding (received) of
2) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 0 Pain Relevance 0
HN or its non-IGFBP-3 binding analogues may provide potential therapeutic options for prevention or treatment of at least two age-related diseases, namely impaired carbohydrate metabolism/T2DM and neurodegeneration.



HN Binding (binding) of associated with diabetes mellitus and disease
3) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 1.01 Pain Relevance 0
To assess if IGFBP-3 attenuates the effects of HN on insulin action, we utilized a series of HN analogues that do not bind to IGFBP-3 (Fig. 4A).
HN Binding (bind) of
4) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 0.17 Pain Relevance 0
We have separately shown that IGFBP-3 also binds HN and antagonizes its survival effects [11].
HN Binding (binds) of
5) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 0.14 Pain Relevance 0
We previously demonstrated that HN physically binds with IGFBP-3 and that this interaction prevents the activation of caspases [11].
HN Binding (binds) of
6) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 0.79 Pain Relevance 0
A recent study has demonstrated that HN protects neurons by binding to a complex or complexes involving CNTFR/WSX-1/gp130 [13].
HN Binding (binding) of in neurons
7) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709436 Disease Relevance 1.08 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox